Page last updated: 2024-10-22

acetazolamide and Hemoglobin C Disease

acetazolamide has been researched along with Hemoglobin C Disease in 1 studies

Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)

Hemoglobin C Disease: A disease characterized by compensated hemolysis with a normal hemoglobin level or a mild to moderate anemia. There may be intermittent abdominal discomfort, splenomegaly, and slight jaundice.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goldberg, MF1

Other Studies

1 other study available for acetazolamide and Hemoglobin C Disease

ArticleYear
The diagnosis and treatment of secondary glaucoma after hyphema in sickle cell patients.
    American journal of ophthalmology, 1979, Volume: 87, Issue:1

    Topics: Acetazolamide; Adolescent; Adult; Anemia, Sickle Cell; Black People; Child; Drug Evaluation; Female;

1979